Alzamend Neuro, Inc. ALZN
NASDAQ
| 07/31/2026 | 04/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -20.42% | 165.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.38% | 30.63% | |||
| Operating Income | -5.38% | -30.63% | |||
| Income Before Tax | -5.47% | -30.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5.47% | -30.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.47% | -30.51% | |||
| EBIT | -5.38% | -30.63% | |||
| EBITDA | -5.43% | -31.02% | |||
| EPS Basic | 6.22% | -24.69% | |||
| Normalized Basic EPS | 6.22% | -24.70% | |||
| EPS Diluted | 6.22% | -24.69% | |||
| Normalized Diluted EPS | 6.22% | -24.70% | |||
| Average Basic Shares Outstanding | 12.47% | 4.67% | |||
| Average Diluted Shares Outstanding | 12.47% | 4.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||